IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapeutics. Their approach centers on identifying and validating translational biomarkers and then using them to select patient populations most likely to benefit from their targeted therapies. IDEAYA's research and drug discovery capabilities are applied to synthetic lethality, an emerging class of precision medicine targets, as well as direct targeting of oncogenic pathways.

IDEAYA has built a robust pipeline of potential first-in-class and/or best-in-class precision medicine therapeutics. Their most advanced programs include darovasertib (IDE196), a clinical-stage PKC inhibitor for genetically-defined cancers; IDE397, a clinical-stage MAT2A inhibitor targeting patients with tumors having MTAP gene deletion; and IDE161, a clinical-stage PARG inhibitor for patients having tumors with homologous recombination deficiency (HRD). IDEAYA is headquartered in South San Francisco, California.

IDEAYA Biosciences operates on a hybrid work model, requiring all employees to be on-site at the office four days a week and allowing one day of remote work. This approach prioritizes in-person collaboration while recognizing the value of flexibility.

IDEAYA Biosciences offers a competitive compensation package that includes equity participation, a comprehensive benefits package, and a commitment to employee well-being. The company's benefits package aims to reward employees for their contributions and encourages health and future planning. This includes health insurance, dental, vision, retirement savings, and other benefits, all aimed at supporting employees and their families.

IDEAYA Biosciences is a clinical-stage precision medicine oncology company focused on developing targeted therapeutics for specific patient populations identified through molecular diagnostics. Their mission is to discover and develop innovative therapies that have the potential to be first-in-class or best-in-class, with a primary focus on synthetic lethality, an emerging class of precision medicine targets. IDEAYA is committed to improving lives by delivering transformative precision medicines to cancer patients.

IDEAYA Biosciences fosters a culture of passion, innovation, and teamwork. They value attracting top talent and encourage a collaborative environment, believing that a diverse and empowered team is key to delivering transformative precision medicines for cancer patients. They emphasize a commitment to integrity, objective decision-making, and taking ownership, promoting a culture of accountability and continuous learning. This drive for innovation is combined with a strong focus on their mission, creating a dynamic and purpose-driven work environment.

IDEAYA Biosciences is committed to fostering a diverse, equitable, and inclusive workplace. They believe in the importance of attracting and retaining exceptional talent from all backgrounds and are dedicated to creating a culture where everyone feels valued, respected, and empowered to contribute their unique perspectives and experiences. IDEAYA embraces a hybrid work model that emphasizes on-site collaboration while providing flexibility for remote work. They offer competitive compensation and benefits, including equity participation, to reward employees and encourage their growth and success within the company.